Tasly Corporation proposes total dividend per share of 0.31 yuan for the full year

(Source: Caixin)

The company’s total cash dividends for the year (including the cash dividends paid in the first half of the year) amount to 463,124,501.55 RMB, accounting for 41.91% of the net profit attributable to shareholders of the parent company in the consolidated financial statements for 2025.

On the evening of March 19, Tasly (600535.SH) released its first annual report after joining the China Resources Sanjiu system. The company’s net profit attributable to the parent in 2025 was 1.105 billion RMB, a year-on-year increase of 15.63%. Basic earnings per share were 0.74 RMB, up 15.63% year-on-year. Tasly has always actively responded to regulatory calls by increasing investor returns through cash dividends and other methods. This time, it also announced a planned dividend of 0.1 RMB (including tax), bringing the total annual dividend to 0.31 RMB per share.

Dividend payout ratio since listing exceeds 40%

Tasly’s annual report shows that the basic earnings per share were 0.74 RMB, a 15.63% increase year-on-year. The company’s high-quality development has driven profit growth and increased returns to investors. The listed company plans to distribute a cash dividend of 0.1 RMB (including tax) per share to all shareholders. The company has already implemented profit distribution for the first half of 2025, with a cash dividend of 0.21 RMB per share (including tax). The total cash dividends for this year (including those paid in the first half) amount to 463,124,501.55 RMB, representing 41.91% of the net profit attributable to shareholders in the 2025 consolidated financial statements.

Tasly has always actively responded to regulatory encouragement for listed companies to enhance investor returns through cash dividends and other means. In 2024, Tasly conducted three dividend distributions throughout the year, totaling 0.53 RMB per share. Since its listing, the company’s dividend payout ratio has exceeded 40%.

Steady and sound business performance

The annual report shows that during the reporting period, the company’s operating performance was stable, with operating revenue of 8.236 billion RMB. Of this, the main business revenue from pharmaceuticals was 7.382 billion RMB, remaining relatively stable; net profit attributable to shareholders was 1.105 billion RMB, a 15.63% increase year-on-year.

Among the company’s three major business segments, cardiovascular and metabolic products generated 4.067 billion RMB; neurology and mental health products generated 1.412 billion RMB; and digestive health products generated 986 million RMB, with a year-on-year growth of 3.91%.

For 2025, the company’s R&D investment reached 845 million RMB. As of now, it has 31 ongoing innovative drugs, including 4 in NDA/Pre-NDA stages and 17 in Phase II and III clinical trials. Cinda Securities recently reported that the market generally perceives the company as a traditional enterprise mainly focused on Chinese medicine, with limited attention to its innovation and transformation. However, the company’s rich R&D pipeline presents valuation re-rating opportunities.